US Stock MarketDetailed Quotes

VRTX Vertex Pharmaceuticals

Watchlist
  • 429.930
  • +7.150+1.69%
Close May 13 16:00 ET
  • 430.500
  • +0.570+0.13%
Post 19:29 ET
110.94BMarket Cap27.90P/E (TTM)

Vertex Pharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
(Q3)Sep 30, 2022
(Q2)Jun 30, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
45.19%1.31B
-14.35%3.54B
-78.25%234.6M
32.75%1.27B
-0.47%1.13B
-5.89%899.9M
56.23%4.13B
8.38%1.08B
3.05%955.5M
670.76%1.14B
Net income from continuing operations
57.13%1.1B
8.96%3.62B
18.31%968.8M
11.26%1.04B
12.98%915.7M
-8.17%699.8M
41.84%3.32B
6.34%818.9M
9.23%930.5M
1,109.70%810.5M
Operating gains losses
521.88%27M
-99.60%600K
-93.33%400K
137.13%6.2M
-99.52%400K
-108.47%-6.4M
971.93%149.1M
149.59%6M
64.24%-16.7M
894.34%84.2M
Depreciation and amortization
37.89%53.5M
22.25%181.3M
53.65%59M
14.71%42.1M
10.99%41.4M
8.08%38.8M
18.07%148.3M
13.61%38.4M
15.77%36.7M
19.17%37.3M
Deferred tax
-39.59%-158.3M
-94.45%-536.5M
-188.45%-131M
36.64%-115.5M
23.02%-176.6M
-821.95%-113.4M
-78.46%-275.9M
453.46%148.1M
-367.30%-182.3M
3.57%-229.4M
Other non cash items
-283.84%-36.4M
5.47%-43.2M
-169.61%-32.3M
32.99%-19.5M
81.46%-11.2M
861.54%19.8M
-504.42%-45.7M
672.84%46.4M
-377.14%-29.1M
-675.24%-60.4M
Change In working capital
-6.91%129.3M
-177.96%-265.7M
-822.88%-838.9M
133.79%188.9M
-36.04%245.4M
523.48%138.9M
423.95%340.8M
-167.53%-90.9M
188.40%80.8M
333.11%383.7M
-Change in receivables
-178.01%-251.6M
76.55%-84.1M
50.98%15.4M
94.90%-6.1M
96.55%-2.9M
45.22%-90.5M
-30.54%-358.6M
123.45%10.2M
35.51%-119.5M
-260.19%-84.1M
-Change in inventory
3.03%-80.1M
-136.73%-322.9M
10.60%-70M
-263.81%-97.5M
-118.62%-72.8M
-4,230.00%-82.6M
-46.98%-136.4M
-190.00%-78.3M
-46.45%-26.8M
-34.82%-33.3M
-Change in prepaid assets
114.72%99.2M
-67.19%-545.7M
-58.63%-451.3M
4.87%-121M
-210.73%-19.6M
-31.66%46.2M
-255.56%-326.4M
-1,889.31%-284.5M
-720.65%-127.2M
122.43%17.7M
-Change in payables and accrued expense
10.09%194.2M
-27.92%478.1M
-39.80%-388.5M
4.02%377.9M
-41.16%312.3M
274.52%176.4M
96.65%663.3M
-364.41%-277.9M
143.83%363.3M
996.62%530.8M
-Change in other current liabilities
87.47%167.6M
-58.13%208.9M
-89.71%55.5M
495.56%35.6M
159.92%28.4M
469.43%89.4M
2,869.64%498.9M
541.62%539.6M
57.75%-9M
12.71%-47.4M
Cash from discontinued investing activities
Operating cash flow
45.19%1.31B
-14.35%3.54B
-78.25%234.6M
32.75%1.27B
-0.47%1.13B
-5.89%899.9M
56.23%4.13B
8.38%1.08B
3.05%955.5M
670.76%1.14B
Investing cash flow
Cash flow from continuing investing activities
-16.51%-2.14B
-878.42%-3.14B
-604.84%-886.5M
69.36%-117.7M
-394.15%-303.9M
-3,495.29%-1.83B
5.81%-321.1M
231.04%175.6M
-626.28%-384.2M
22.84%-61.5M
Net PPE purchase and sale
-62.47%-68.4M
2.10%-200.4M
-72.92%-58.1M
25.09%-40.6M
-11.82%-59.6M
33.81%-42.1M
12.89%-204.7M
45.63%-33.6M
-3.44%-54.2M
-6.81%-53.3M
Net intangibles purchase and sale
---180M
---58M
----
----
----
--0
--0
----
----
----
Net business purchase and sale
----
--0
--0
----
----
----
---295.9M
--0
----
----
Net investment purchase and sale
-5.39%-1.89B
-1,706.30%-2.88B
-468.26%-770.4M
-126.10%-77.1M
-2,879.27%-244.3M
-14,318.25%-1.79B
269.50%179.5M
389.75%209.2M
-6,720.00%-34.1M
72.48%-8.2M
Cash from discontinued investing activities
Investing cash flow
-16.51%-2.14B
-878.42%-3.14B
-604.84%-886.5M
69.36%-117.7M
-394.15%-303.9M
-3,495.29%-1.83B
5.81%-321.1M
231.04%175.6M
-626.28%-384.2M
22.84%-61.5M
Financing cash flow
Cash flow from continuing financing activities
-21.31%-357.5M
-730.43%-562.2M
-398.01%-119.8M
-174.09%-165M
-63.73%17.3M
-208.91%-294.7M
95.42%-67.7M
111.96%40.2M
90.83%-60.2M
41.96%47.7M
Net issuance payments of debt
-24.53%-13.2M
47.44%-43.1M
-47.83%-10.2M
77.17%-11.3M
13.39%-11M
17.83%-10.6M
-338.50%-82M
-309.09%-6.9M
-345.95%-49.5M
-452.17%-12.7M
Net common stock issuance
-21.81%-364.7M
-280.06%-653.7M
-7,171.43%-152.7M
-254.58%-170.2M
-613.64%-31.4M
-154.81%-299.4M
88.98%-172M
99.43%-2.1M
92.74%-48M
-22.22%-4.4M
Proceeds from stock option exercised by employees
19.01%16.9M
-27.75%134.6M
-10.08%46.4M
-57.92%15.4M
-9.01%58.6M
-57.86%14.2M
82.65%186.3M
48.70%51.6M
165.22%36.6M
69.92%64.4M
Net other financing activities
218.18%3.5M
----
----
57.14%1.1M
175.00%1.1M
-15.38%1.1M
----
----
-50.00%700K
-75.00%400K
Cash from discontinued financing activities
Financing cash flow
-21.31%-357.5M
-730.43%-562.2M
-398.01%-119.8M
-174.09%-165M
-63.73%17.3M
-208.91%-294.7M
95.42%-67.7M
111.96%40.2M
90.83%-60.2M
41.96%47.7M
Net cash flow
Beginning cash position
-1.33%10.37B
54.59%10.51B
21.14%11.12B
16.65%10.15B
22.25%9.3B
54.59%10.51B
13.55%6.8B
46.13%9.18B
43.37%8.7B
20.45%7.6B
Current changes in cash
3.35%-1.19B
-104.45%-166.6M
-159.63%-771.7M
92.86%985.7M
-24.71%847.8M
-251.69%-1.23B
353.69%3.74B
146.61%1.29B
134.88%511.1M
558.10%1.13B
Effect of exchange rate changes
-230.00%-15.6M
192.12%26.9M
-32.84%27.4M
41.10%-22.5M
138.61%10M
303.39%12M
-117.91%-29.2M
932.65%40.8M
-349.41%-38.2M
-747.50%-25.9M
End cash Position
-1.36%9.17B
-1.33%10.37B
-1.33%10.37B
21.14%11.12B
16.65%10.15B
22.25%9.3B
54.59%10.51B
54.59%10.51B
46.13%9.18B
43.37%8.7B
Free cash flow
23.36%1.06B
-16.47%3.28B
-88.66%118.5M
36.23%1.23B
-1.08%1.07B
-3.90%857.8M
62.97%3.93B
11.96%1.04B
3.03%901.3M
535.30%1.09B
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
Unqualified Opinion
--
--
--
--
--
--
--
--
(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022(Q3)Sep 30, 2022(Q2)Jun 30, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities 45.19%1.31B-14.35%3.54B-78.25%234.6M32.75%1.27B-0.47%1.13B-5.89%899.9M56.23%4.13B8.38%1.08B3.05%955.5M670.76%1.14B
Net income from continuing operations 57.13%1.1B8.96%3.62B18.31%968.8M11.26%1.04B12.98%915.7M-8.17%699.8M41.84%3.32B6.34%818.9M9.23%930.5M1,109.70%810.5M
Operating gains losses 521.88%27M-99.60%600K-93.33%400K137.13%6.2M-99.52%400K-108.47%-6.4M971.93%149.1M149.59%6M64.24%-16.7M894.34%84.2M
Depreciation and amortization 37.89%53.5M22.25%181.3M53.65%59M14.71%42.1M10.99%41.4M8.08%38.8M18.07%148.3M13.61%38.4M15.77%36.7M19.17%37.3M
Deferred tax -39.59%-158.3M-94.45%-536.5M-188.45%-131M36.64%-115.5M23.02%-176.6M-821.95%-113.4M-78.46%-275.9M453.46%148.1M-367.30%-182.3M3.57%-229.4M
Other non cash items -283.84%-36.4M5.47%-43.2M-169.61%-32.3M32.99%-19.5M81.46%-11.2M861.54%19.8M-504.42%-45.7M672.84%46.4M-377.14%-29.1M-675.24%-60.4M
Change In working capital -6.91%129.3M-177.96%-265.7M-822.88%-838.9M133.79%188.9M-36.04%245.4M523.48%138.9M423.95%340.8M-167.53%-90.9M188.40%80.8M333.11%383.7M
-Change in receivables -178.01%-251.6M76.55%-84.1M50.98%15.4M94.90%-6.1M96.55%-2.9M45.22%-90.5M-30.54%-358.6M123.45%10.2M35.51%-119.5M-260.19%-84.1M
-Change in inventory 3.03%-80.1M-136.73%-322.9M10.60%-70M-263.81%-97.5M-118.62%-72.8M-4,230.00%-82.6M-46.98%-136.4M-190.00%-78.3M-46.45%-26.8M-34.82%-33.3M
-Change in prepaid assets 114.72%99.2M-67.19%-545.7M-58.63%-451.3M4.87%-121M-210.73%-19.6M-31.66%46.2M-255.56%-326.4M-1,889.31%-284.5M-720.65%-127.2M122.43%17.7M
-Change in payables and accrued expense 10.09%194.2M-27.92%478.1M-39.80%-388.5M4.02%377.9M-41.16%312.3M274.52%176.4M96.65%663.3M-364.41%-277.9M143.83%363.3M996.62%530.8M
-Change in other current liabilities 87.47%167.6M-58.13%208.9M-89.71%55.5M495.56%35.6M159.92%28.4M469.43%89.4M2,869.64%498.9M541.62%539.6M57.75%-9M12.71%-47.4M
Cash from discontinued investing activities
Operating cash flow 45.19%1.31B-14.35%3.54B-78.25%234.6M32.75%1.27B-0.47%1.13B-5.89%899.9M56.23%4.13B8.38%1.08B3.05%955.5M670.76%1.14B
Investing cash flow
Cash flow from continuing investing activities -16.51%-2.14B-878.42%-3.14B-604.84%-886.5M69.36%-117.7M-394.15%-303.9M-3,495.29%-1.83B5.81%-321.1M231.04%175.6M-626.28%-384.2M22.84%-61.5M
Net PPE purchase and sale -62.47%-68.4M2.10%-200.4M-72.92%-58.1M25.09%-40.6M-11.82%-59.6M33.81%-42.1M12.89%-204.7M45.63%-33.6M-3.44%-54.2M-6.81%-53.3M
Net intangibles purchase and sale ---180M---58M--------------0--0------------
Net business purchase and sale ------0--0---------------295.9M--0--------
Net investment purchase and sale -5.39%-1.89B-1,706.30%-2.88B-468.26%-770.4M-126.10%-77.1M-2,879.27%-244.3M-14,318.25%-1.79B269.50%179.5M389.75%209.2M-6,720.00%-34.1M72.48%-8.2M
Cash from discontinued investing activities
Investing cash flow -16.51%-2.14B-878.42%-3.14B-604.84%-886.5M69.36%-117.7M-394.15%-303.9M-3,495.29%-1.83B5.81%-321.1M231.04%175.6M-626.28%-384.2M22.84%-61.5M
Financing cash flow
Cash flow from continuing financing activities -21.31%-357.5M-730.43%-562.2M-398.01%-119.8M-174.09%-165M-63.73%17.3M-208.91%-294.7M95.42%-67.7M111.96%40.2M90.83%-60.2M41.96%47.7M
Net issuance payments of debt -24.53%-13.2M47.44%-43.1M-47.83%-10.2M77.17%-11.3M13.39%-11M17.83%-10.6M-338.50%-82M-309.09%-6.9M-345.95%-49.5M-452.17%-12.7M
Net common stock issuance -21.81%-364.7M-280.06%-653.7M-7,171.43%-152.7M-254.58%-170.2M-613.64%-31.4M-154.81%-299.4M88.98%-172M99.43%-2.1M92.74%-48M-22.22%-4.4M
Proceeds from stock option exercised by employees 19.01%16.9M-27.75%134.6M-10.08%46.4M-57.92%15.4M-9.01%58.6M-57.86%14.2M82.65%186.3M48.70%51.6M165.22%36.6M69.92%64.4M
Net other financing activities 218.18%3.5M--------57.14%1.1M175.00%1.1M-15.38%1.1M---------50.00%700K-75.00%400K
Cash from discontinued financing activities
Financing cash flow -21.31%-357.5M-730.43%-562.2M-398.01%-119.8M-174.09%-165M-63.73%17.3M-208.91%-294.7M95.42%-67.7M111.96%40.2M90.83%-60.2M41.96%47.7M
Net cash flow
Beginning cash position -1.33%10.37B54.59%10.51B21.14%11.12B16.65%10.15B22.25%9.3B54.59%10.51B13.55%6.8B46.13%9.18B43.37%8.7B20.45%7.6B
Current changes in cash 3.35%-1.19B-104.45%-166.6M-159.63%-771.7M92.86%985.7M-24.71%847.8M-251.69%-1.23B353.69%3.74B146.61%1.29B134.88%511.1M558.10%1.13B
Effect of exchange rate changes -230.00%-15.6M192.12%26.9M-32.84%27.4M41.10%-22.5M138.61%10M303.39%12M-117.91%-29.2M932.65%40.8M-349.41%-38.2M-747.50%-25.9M
End cash Position -1.36%9.17B-1.33%10.37B-1.33%10.37B21.14%11.12B16.65%10.15B22.25%9.3B54.59%10.51B54.59%10.51B46.13%9.18B43.37%8.7B
Free cash flow 23.36%1.06B-16.47%3.28B-88.66%118.5M36.23%1.23B-1.08%1.07B-3.90%857.8M62.97%3.93B11.96%1.04B3.03%901.3M535.30%1.09B
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions --Unqualified Opinion----------------

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg
Concept Gene Editing
Gene Editing
Intraday+1.27%